Apr 09, 2013
National MS Society
National MS Society/Fast Forward, LLC Funds Accera and University of Miami in Collaboration to Study Axona® for Cognitive Impairment in Patients with MS
Accera, Inc., a privately-held, commercial-stage, healthcare company focused on the discovery and development of innovative clinical applications to address acute and chronic neurodegenerative diseases, announced a study in collaboration with the University of Miami Miller School of Medicine. The study will examine the effects of Accera’s medical food, Axona, on cognitive impairment in patients with multiple sclerosis (MS). Axona is a prescription medical food intended for the clinical dietary management of the metabolic processes associated with mild to moderate Alzheimer’s disease (AD). Drs. Melissa Ortega and Heather Katzen, two researchers at the Miller School, will serve as the primary investigators of the study. The project will be funded by Fast Forward, LLC, a nonprofit organization established by the National Multiple Sclerosis Society.
Fast Forward, LLC, established by the National Multiple Sclerosis Society as part of a comprehensive approach to MS research and treatment, focuses on speeding promising research discoveries towards commercial drug development. Fast Forward accelerates the development of treatments for MS by connecting university-based MS research with private-sector drug development and by funding small biotechnology/pharmaceutical companies to develop innovative new MS therapies and repurpose FDA-approved drugs as new treatments for MS.
Cognitive problems commonly occur in the more than 2.1 million people that are affected by MS worldwide. Symptoms vary in severity and may have a negative impact on relationships, work and quality of life. There is a pressing need for new interventions for cognitive impairment in MS. The UM Miller School of Medicine and Accera, with support from Fast Forward, LLC, will be testing Axona as a unique strategy for improving cognitive function in individuals with MS to address this disabling symptom.
“We are very excited about this project,” said Holger Kunze, CEO at Accera. “This collaboration fits well with Accera’s mission to help patients with neurological disorders by addressing metabolic deficiencies common in these disease states.”
To participate in the trial please contact: Gloria Rodriguez, coordinator at University of Miami Miller School of Medicine at (305) 243-8052. For information on funding this study contact: Mark Kotler at the National MS Society (954) 731-4224 or email@example.com